Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [QUIET] · [POLITICS]
2 clusters · 3 sources · 16 days · First seen · Last updated
US administration prescription drug pricing policies
Overview
The Trump administration has focused on reducing costs for prescription drugs, with the White House claiming credit for a significant year-over-year decline in prices. While the administration attributes these shifts to its own actions, reports suggest experts link the drop to Biden-era policies, specifically the Inflation Reduction Act, which enables Medicare to negotiate prices for certain high-expenditure drugs.
To further address healthcare affordability, the administration announced new voluntary ‘Most Favored Nation’ (MFN) drug-pricing agreements. Under this framework, manufacturers such as Bayer, Takeda, and CSL agree to align U.S. prices with the lowest prices found in other high-income nations like Canada and Japan. The administration noted that previous MFN deals contributed to a 3.1% year-over-year drop in prescription drug prices.
Entities
Donald Trump · Bayer · Joe Biden · Medicare · The Washington Post
Timeline
-
11 days ago
[POLITICS] 3 sourcesTrump administration targets drug and gas affordabilityPresident Trump is advancing drug-pricing agreements through the Most Favored Nation framework to lower costs, while gas prices decline and critics warn a new Department of Labor rule could increase expenses.
-
27 days ago
[POLITICS] 8 sourcesTrump claims credit for major drop in prescription drug pricesThe White House is claiming credit for a major drop in prescription drug prices, though experts cited in a Washington Post report attribute the decline to Biden-era Medicare negotiation policies.
Sources
justthenews.com · msnbc.com · pcmanet.org